101. Clinical performance of (68)Ga-PSMA-11 PET/MRI for the detection of recurrent prostate cancer following radical prostatectomy
- Author
-
Martin W. Huellner, Urs J. Muehlematter, Hannes W. Nagel, Philipp A. Kaufmann, Julian Müller, Paul Stolzmann, Benedikt Kranzbühler, Matthias Guckenberger, Irene A. Burger, Daniel Eberli, Anton S. Becker, University of Zurich, and Burger, Irene A
- Subjects
Biochemical recurrence ,PCA3 ,medicine.medical_specialty ,medicine.medical_treatment ,610 Medicine & health ,urologic and male genital diseases ,030218 nuclear medicine & medical imaging ,03 medical and health sciences ,Prostate cancer ,0302 clinical medicine ,Interquartile range ,medicine ,2741 Radiology, Nuclear Medicine and Imaging ,Radiology, Nuclear Medicine and imaging ,Pelvis ,medicine.diagnostic_test ,business.industry ,Prostatectomy ,General Medicine ,10181 Clinic for Nuclear Medicine ,medicine.disease ,10044 Clinic for Radiation Oncology ,Prostate-specific antigen ,10062 Urological Clinic ,medicine.anatomical_structure ,Positron emission tomography ,030220 oncology & carcinogenesis ,Radiology ,Nuclear medicine ,business - Abstract
Sensitive visualization of recurrent prostate cancer foci is a challenge in patients with early biochemical recurrence (EBR). The recently established 68Ga-PSMA-11 PET/CT has significantly improved the detection rate with published values of up to 55% for patients with a serum PSA concentration between 0.2–0.5 ng/mL. The increased soft tissue contrast in the pelvis using simultaneous 68Ga-PSMA-11 PET/MRI might further improve the detection rate in patients with EBR and low PSA values over PET/CT. We retrospectively analyzed a cohort of 56 consecutive patients who underwent a 68Ga-PSMA-11 PET/MRI for biochemical recurrence in our institution between April and December 2016 with three readers. Median PSA level was 0.99 ng/mL (interquartile range: 3.1 ng/mL). Detection of PSMA-positive lesions within the prostate fossa, local and distant lymph nodes, bones, or visceral organs was recorded. Agreement among observers was evaluated with Fleiss’s kappa (k). Overall, in 44 of 56 patients (78.6%) PSMA-positive lesions were detected. In four of nine patients (44.4%) with a PSA 2.0 ng/mL, suspicious lesions were detected. The overall interreader agreement for cancer detection was excellent (κ = 0.796, CI 0.645–0.947). Our data show that 68Ga-PSMA-11 PET/MRI has a high detection rate for recurrent prostate cancer even at very low PSA levels
- Published
- 2018
- Full Text
- View/download PDF